Huanyu Xiang

Dr. Huanyu Xiang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
HXHuanyu Xiang
Huanyu Xiang
THTaiyu He
Taiyu He
YDYanling Dou
Yanling Dou
QCQingwei Chen
Qingwei Chen
PWPeiyu Wu
Peiyu Wu
JZJie Zhang
Jie Zhang
Background: Individuals with chronic hepatitis B virus (HBV) infection present with gut dysbiosis. Evidence suggests that gut microbiota can affect the efficacy of anti-HBV therapy. However, limited research has comprehensively explored how gut microbiota and its related metabolites interact with HBV treatment response after antiviral treatment. Our study aims to identify an association between the dominant microbial cluster and HBV treatment response during anti-viral therapies. Methods: HBV carrier mice were utilized to assess the antiviral efficacy and peripheral and intrahepatic immune responses of entecavir (ETV) and ETV plus interferon-α (EI) therapies. We analyzed the gut microbiome, metabolome, and non-parenchymal hepatic cells transcriptome to determine the role of gut microbes and related metabolites in virological and intrahepatic immune responses to ETV and EI. Mice receiving no therapy (HBV control), ETV monotherapy, and EI therapy were used for comparison. Furthermore, we used immune cells to evaluate the effects of metabolites produced by the identified bacteria. Results: EI therapy showed a greater trend toward reducing serum HBsAg and HBeAg levels compared with ETV monotherapy, and significantly decreased intrahepatic HBcAg expression. Principal coordinates analysis revealed that gut microbes and metabolites were significantly different in the EI treatment group and the ETV and HBV groups. Notably, the relative abundance of short-chain fatty acid-producing bacteria was higher in the EI group, particularly in gut Roseburia abundance and butyrate levels. Butyrate levels were also elevated in the liver. However, whether this reflects intestinal absorption or hepatic synthesis remains undetermined. Butyrate is a potent inhibitor of histone deacetylases (HDACs), which can reduce the expression of hepatic HDAC and also suppress its activity. Hepatic HDAC1 protein levels were lower in the EI group than ETV group, consistent with the possibility that butyrate may modulate HDAC1 expression. Furthermore, EI treatment increased hepatic NKG2D+ NK cells and upregulated the NK cell-mediated cytotoxicity pathway. In vitro studies revealed that 0.5 mM butyrate enhanced the cytokine response of CD8+ T cells to HBV surface-specific antigens. Conclusions: Our multi-omics analysis reveals an association of gut Roseburia abundance and butyrate levels with improved virological responses to EI therapy. In vitro, butyrate enhanced the cytokine response of HBV-specific CD8+ T cells, suggesting a hypothesis that butyrate (but does not verify mediation of the virological responses to EI) may contribute to the antiviral response. While our multi-omics and in vitro data support a testable working hypothesis that butyrate may contribute to intrahepatic immune modulation, we acknowledge that causality is not established by this study. These results provide potential possibilities for future functional investigations of butyrate-producing microbiota as an adjunct to anti-HBV therapy.

12 September 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
HXHongyan Xiang
Hongyan Xiang
HXHuanyu Xiang
Huanyu Xiang
ZLZongyi Liu
Zongyi Liu
SLShan Liu
Shan Liu
ZLZhidan Luo
Zhidan Luo
JZJie Zhang
Jie Zhang
The gut microbiota plays a critical role in regulating liver metabolism and immunity, significantly influencing hepatic inflammation and fibrogenesis. However, the mechanisms by which it modulates the progression of liver fibrosis remain unclear. This study investigated the interplay between the gut microbiota and bile acids in murine liver fibrosis. A mouse model of liver fibrosis was established via intraperitoneal injection of carbon tetrachloride. The gut microbiota was depleted using an antibiotic cocktail, as confirmed through 16S rRNA sequencing. Bile acid profiles were measured using ultra-performance liquid chromatography–tandem mass spectrometry. The effects of secondary bile acids on macrophage polarization were assessed in vivo and in vitro. Gut commensal microbiota depletion exacerbated liver inflammation and fibrosis. Concomitantly, this depletion significantly reduced microbiota-derived secondary bile acids. Notably, supplementation with deoxycholic acid markedly attenuated liver fibrosis. This protective effect was associated with the inhibition of pro-inflammatory M1 macrophage polarization. Takeda G protein-coupled receptor 5 (TGR5) activation was identified as the mechanism underlying the effect of deoxycholic acid on macrophages, as a TGR5 antagonist reversed this inhibition. Mechanistically, TGR5 activation suppressed the NF-κB pathway in macrophages via the cAMP–PKA signaling cascade, thereby inhibiting hepatic stellate cell activation. Our results demonstrate that the gut microbiota–secondary bile acid–TGR5 signaling axis plays a critical role in liver fibrosis and represents a promising therapeutic target.